Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.
about
Antiangiogenic therapy for high-grade gliomaAngiogenesis-inhibitors for metastatic thyroid cancerAnti-angiogenic therapy for high grade gliomaAnti-angiogenic therapy for lung cancerAnti-angiogenic therapies for metastatic colorectal cancerAnti-angiogenic therapy for metastatic colorectal cancerDendritic Polymers for TheranosticsAngiostatin inhibits pancreatic cancer cell proliferation and growth in nude mice.Expression of angiostatin cDNA in human gallbladder carcinoma cell line GBC-SD and its effect on endothelial proliferation and growth.Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment.Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinibThe effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinomaDetection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate.Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.Theranostic tumor homing nanocarriers for the treatment of lung cancerFucans, but not fucomannoglucuronans, determine the biological activities of sulfated polysaccharides from Laminaria saccharina brown seaweed.Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration.Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative studyDiscrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy.Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications.PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: in vitro cell line study to ensure advantage of combination therapy.Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells.Evaluation of Antitumor Activity of Long-Circulating and pH-Sensitive Liposomes Containing Ursolic Acid in Animal Models of Breast Tumor and Gliosarcoma.Thalidomide and irradiation combination therapy increases substance P levels in vitroc-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarraysIs nonangiogenesis a novel pathway for cancer progression? A study using 3-dimensional tumour reconstructionsComparison of simple models of periodic protocols for combined anticancer therapyGene translocations in musculoskeletal neoplasms.Targeted therapies for soft-tissue sarcomas.Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.Antiangiogenic agents in breast cancer.Development of antiangiogenic agents for ovarian cancer.Recombinant vascular basement-membrane-derived multifunctional peptide inhibits angiogenesis and growth of hepatocellular carcinoma.Bevacizumab in the treatment of HER2-negative breast cancer.Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lungEnhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.Bevacizumab: overview of the literature.Combined chemotherapy delivered by nanoparticulate systems: an old concept with modern innovations.
P2860
Q24193485-B1700C8B-FBE1-4214-951D-478D878D640FQ24236743-B83F48B6-B0CA-442B-A915-6B74D9F8A925Q24240185-789B7D22-D984-4C8A-B3B5-A7C9566C4CA9Q24240857-E1003E6F-15AE-412E-A48B-7429D9682376Q24241813-8282BD08-711C-4F74-B2DB-477F47B6496EQ24243297-43A97533-FB20-417F-9BC9-D049332FCCE9Q26746182-02E5C951-C034-415D-AAA9-683A587DB69CQ33222336-862E4827-2F35-4A1F-8020-F9E46B7262B7Q33244333-F40908AF-41B8-4DF7-9A41-D05D2DFE76B2Q33395123-481EC8B6-682B-4593-8AFF-A6BA9C45BFB8Q33400232-606B6D9F-F2F5-454B-971F-79D7B472CCECQ33514437-20421477-0F30-475D-BDC9-B6B269A2EBAAQ33576784-C65BFAEC-11B1-4018-9BEF-06911CF3453FQ33675186-116CAADF-2CFD-445B-9008-CC4A0C600726Q33769951-E643B259-B1FE-4216-B705-8DE3B86B774AQ33841032-C159A449-6FA9-4F66-865C-EF1B009D7BD0Q34130424-4C787753-7AD9-404F-8305-5FD8CE990358Q34497997-AAEB9FE0-8EEF-4CCE-B19E-0F3C42897658Q35061280-7551D20E-28AC-41FE-988F-3FF8EEF21B5EQ35069292-2094D1A3-BD98-400C-823C-A02AE5C4F016Q35444368-33DE2809-EF93-45BE-A6B3-FEF1DF0B0F7DQ35570450-93FFC91A-083B-4C4C-83F1-2F8D8FCF2B7DQ35673296-5770C6FB-5AAD-44B7-951D-8B3B4D02887DQ35797575-A4EFE6E7-6015-4092-8E53-EB6E2BD693AFQ36004070-A282E5ED-BF15-426C-AEE6-135BE512B1A5Q36230673-0D1EABF3-49D0-4BCD-A99D-D2E847CEC147Q36609706-3DA059EB-556B-46F0-94F8-758FC1A4B845Q36614128-A4240CB6-576E-4122-8270-D69513C2AAE7Q36801962-DD950B30-92F7-4C17-8C23-254BB932F596Q36803632-0D190D06-2D62-420E-A8C7-B18D44D4418CQ36817135-7CEF5274-2140-4204-85CB-5F3711C1DED8Q36982114-F28D1C58-A69A-4FF3-A411-B2922BF1CFE2Q37008618-ABE32D04-0028-441E-A084-26A14018EFE3Q37038884-A359F2E9-70F3-493B-A3AA-B2A5A3AAD210Q37157832-7E73FD92-91D9-4A6D-9736-2A5AAAB80A61Q37307819-EEA90E6D-07D2-487A-B074-DCA26E4F876AQ37308766-BB64BBA1-D2F9-4DFB-B3FD-7BBF60D7F345Q37682915-342D1E42-3AC8-4744-A89D-B919B28299F0Q38010797-7908233F-933C-4016-B05C-89E95A104F7AQ38074438-6A6C84F2-7CDB-4704-B15D-AD6CC7E7D3E5
P2860
Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Combination of antiangiogenic ...... hallenges, and open questions.
@ast
Combination of antiangiogenic ...... hallenges, and open questions.
@en
type
label
Combination of antiangiogenic ...... hallenges, and open questions.
@ast
Combination of antiangiogenic ...... hallenges, and open questions.
@en
prefLabel
Combination of antiangiogenic ...... hallenges, and open questions.
@ast
Combination of antiangiogenic ...... hallenges, and open questions.
@en
P2093
P356
P1476
Combination of antiangiogenic ...... hallenges, and open questions.
@en
P2093
Beverly A Teicher
Giampietro Gasparini
Massimo Fanelli
Raffaele Longo
P304
P356
10.1200/JCO.2005.10.022
P407
P577
2005-02-01T00:00:00Z